PURPOSE: This study sought to determine whether a vascular endothelial growth factor receptor 1 (VEGFR1)-specific morpholino could induce the alternative splicing of Flt-1 pre-mRNA to downregulate membrane-bound Flt-1 (mFlt-1) and increase the production of soluble Flt-1 (sFlt-1), thereby limiting angiogenesis and inflammation in a mouse corneal suture injury model. METHODS: A murine corneal suture model was used to investigate the effects of a VEGFR1-specific morpholino in vivo. Western blot analysis and RT-PCR were used to compare the impact of the Flt morpholino on mFlt-1 and sFlt-1 levels. For vascular regression modeling, two corneal sutures were placed and injected with Flt morpholino, standard morpholino, and PBS on days 8 and 10. Corneas were harvested on day 14. The grade of neovascularization (graded 0-5; 0, no neovascularization; 5, thick tortuous new vessel growth over the suture and toward the center of the cornea) was compared on days 8, 10, and 14. Immunohistochemistry, fluorescent microscopy, and confocal microscopy were used to digitally quantify the area and volume of neovascularization and inflammatory infiltration. RESULTS: Western blot analysis revealed that the Flt morpholino decreased mFlt-1 levels while increasing sFlt-1 levels. An increased sFlt-1/mFlt-1 ratio in the Flt morpholino group was seen with RT-PCR. Based on the neovascularization grading, there was a decrease in neovascularization area in the Flt morpholino group (3.29 ± 0.19 to 2.92 ± 0.13) from day 8 to 14 (P < 0.05) compared with that in both the standard morpholino (2.68 ± 0.19 to 3.14 ± 0.22) and in the PBS (2.96 ± 0.14 to 3.42 ± 0.19) groups, both of which showed an increase in neovascularization (P < 0.05). The Flt morpholino group also showed reduced neovascularization volume compared with that of the PBS (P = 0.001) and STD morpholino groups (P = 0.000). CONCLUSIONS: Flt morpholinos decrease mFlt-1 and increase sFlt-1 levels, resulting in decreased neovascularization in a murine corneal suture model.
PURPOSE: This study sought to determine whether a vascular endothelial growth factor receptor 1 (VEGFR1)-specific morpholino could induce the alternative splicing of Flt-1 pre-mRNA to downregulate membrane-bound Flt-1 (mFlt-1) and increase the production of soluble Flt-1 (sFlt-1), thereby limiting angiogenesis and inflammation in a mousecorneal suture injury model. METHODS: A murine corneal suture model was used to investigate the effects of a VEGFR1-specific morpholino in vivo. Western blot analysis and RT-PCR were used to compare the impact of the Flt morpholino on mFlt-1 and sFlt-1 levels. For vascular regression modeling, two corneal sutures were placed and injected with Flt morpholino, standard morpholino, and PBS on days 8 and 10. Corneas were harvested on day 14. The grade of neovascularization (graded 0-5; 0, no neovascularization; 5, thick tortuous new vessel growth over the suture and toward the center of the cornea) was compared on days 8, 10, and 14. Immunohistochemistry, fluorescent microscopy, and confocal microscopy were used to digitally quantify the area and volume of neovascularization and inflammatory infiltration. RESULTS: Western blot analysis revealed that the Flt morpholino decreased mFlt-1 levels while increasing sFlt-1 levels. An increased sFlt-1/mFlt-1 ratio in the Flt morpholino group was seen with RT-PCR. Based on the neovascularization grading, there was a decrease in neovascularization area in the Flt morpholino group (3.29 ± 0.19 to 2.92 ± 0.13) from day 8 to 14 (P < 0.05) compared with that in both the standard morpholino (2.68 ± 0.19 to 3.14 ± 0.22) and in the PBS (2.96 ± 0.14 to 3.42 ± 0.19) groups, both of which showed an increase in neovascularization (P < 0.05). The Flt morpholino group also showed reduced neovascularization volume compared with that of the PBS (P = 0.001) and STD morpholino groups (P = 0.000). CONCLUSIONS: Flt morpholinos decrease mFlt-1 and increase sFlt-1 levels, resulting in decreased neovascularization in a murine corneal suture model.
Authors: Balamurali K Ambati; Miho Nozaki; Nirbhai Singh; Atsunobu Takeda; Pooja D Jani; Tushar Suthar; Romulo J C Albuquerque; Elizabeth Richter; Eiji Sakurai; Michael T Newcomb; Mark E Kleinman; Ruth B Caldwell; Qing Lin; Yuichiro Ogura; Angela Orecchia; Don A Samuelson; Dalen W Agnew; Judy St Leger; W Richard Green; Parameshwar J Mahasreshti; David T Curiel; Donna Kwan; Helene Marsh; Sakae Ikeda; Lucy J Leiper; J Martin Collinson; Sasha Bogdanovich; Tejvir S Khurana; Masabumi Shibuya; Megan E Baldwin; Napoleone Ferrara; Hans-Peter Gerber; Sandro De Falco; Jassir Witta; Judit Z Baffi; Brian J Raisler; Jayakrishna Ambati Journal: Nature Date: 2006-10-18 Impact factor: 49.962
Authors: Mark Kerber; Yvonne Reiss; Anke Wickersheim; Manfred Jugold; Fabian Kiessling; Matthias Heil; Vadim Tchaikovski; Johannes Waltenberger; Masabumi Shibuya; Karl H Plate; Marcia Regina Machein Journal: Cancer Res Date: 2008-09-15 Impact factor: 12.701
Authors: Wei Zhong; Mario Montana; Samuel M Santosa; Irene D Isjwara; Yu-Hui Huang; Kyu-Yeon Han; Christopher O'Neil; Ashley Wang; Maria Soledad Cortina; Jose de la Cruz; Qiang Zhou; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar Journal: Surv Ophthalmol Date: 2017-12-27 Impact factor: 6.048
Authors: Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Neda Afsharkhamseh; Soroush Besharat; Mark I Rosenblatt; Reza Dana; Peiman Hematti; Ali R Djalilian Journal: Invest Ophthalmol Vis Sci Date: 2017-10-01 Impact factor: 4.799